Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
about
Bisphosphonates: mechanism of action and role in clinical practiceZoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationOff-trial evaluation of bisphosphonates in patients with metastatic breast cancerPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerBone Metastasis from Renal Cell CarcinomaPatient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastasesDiagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementTargeting tumor-stromal interactions in bone metastasisMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.[A systematic review on different treatment methods of bone metastasis from cancers].Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.The evolving role of zoledronic acid in early breast cancerBone health and prostate cancer.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisPreventing bone complications in advanced prostate cancerPotential pathophysiological mechanisms in osteonecrosis of the jaw.Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literatureImproving management of patients with advanced cancerConsequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsNCCN Task Force Report: Bone Health in Cancer Care.Current aproach to cancer pain management: Availability and implications of different treatment options.Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort studyBisphosphonates in Breast Cancer Patients with Bone MetastasesEffects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialIncreased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblastsSystematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasisBone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network.Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.Bone-immune cell crosstalk: bone diseases.Targeting bone as a therapy for myeloma.Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeA randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis
P2860
Q24644708-5AB15FD2-A6A1-4125-8503-97FBFF6F2ABEQ24650864-074D3A1C-04AB-47AD-8582-6434B38807EDQ24811840-1B5A6D64-465D-47D7-96F5-44CD74266C19Q26746212-5A24C553-BD84-47F8-9F19-6DABED3EDF77Q26747493-C086B1BF-A49C-4E04-9AF6-5E0BEB27AF57Q26997330-BC9881D2-954B-4C00-B38B-6AA26FE83C91Q27011865-A5DE8C92-E1E1-440E-9A13-FFC1838A0387Q27024561-5FE10F7D-F2D1-4FDC-9D6A-4AF19393E8D8Q28068956-6A570976-2B92-4A7B-888C-6A120CFDA66FQ33531646-1FED8F13-C456-4169-A817-47610C84A997Q33647258-B9444429-43D4-4A66-9079-034FE3D0E562Q33882079-474A01AD-D032-49D7-AEA9-321AF9E8E883Q33915978-46FDD9DD-A35F-4C1E-8F8E-178A91311591Q33977536-2122A603-75B5-4676-A64D-FA30DBC62FCFQ34042003-318D95C8-0060-4F47-9497-0FCB2AF9A9E8Q34111634-B9EB6CCC-18AA-48A3-A760-ADF9430A18E3Q34162359-710F75A8-6E84-4A47-96EC-DA1B73BDB9FDQ34272136-FDF9913F-81D4-4479-AAED-94D56AE01F2EQ34413634-05B8EAD2-966A-404B-AA0E-5BE01A921D56Q34418934-97B46491-511A-45F4-891C-2CAA8D1720EBQ34427554-20BFA17A-052A-486E-82F7-1AA911DC3448Q34617864-35CD2A4B-2B25-471B-9CDB-E919F54D1E53Q34617936-85770B90-BD01-4BB5-8D74-99C0CD15A75BQ34779398-67CCA4EF-7E58-4089-9F0B-BAEB95973101Q34960635-14D029B6-DE93-4A5A-A3C7-A6AA37933CA2Q35050733-35821E01-B367-402C-90F5-00F9849DF992Q35095548-E84F7F67-69E0-465F-BC29-14AD3C8E26E1Q35141814-23A0F719-DA6B-4E74-BCCC-43440D63676FQ35155516-5D4E5C0C-10A5-4550-88C0-863116DE3C0FQ35231591-B3FC8240-BD86-4ED1-BC67-7485FE215A6AQ35345620-6E31A5BD-319D-40CD-B3BA-255F18049CBDQ35422468-1607BB2A-804F-428E-9EE0-E7F4FD4AEEFDQ35583788-338BDEBB-4197-4558-9692-33C711AB9972Q35584866-434FD37C-B7BD-465F-8A31-A9CE4BFA46FDQ35590055-EA014125-DB5A-499F-9BCE-057C22A74844Q35590612-0727AC66-33CB-49B7-8B3D-0D4703C4CC27Q35592362-D7AD196B-E067-4865-A647-5630109A3ABFQ35603128-32348970-48FD-436C-AE57-2F304B581968Q35667196-91CA399B-47BE-4D87-A49C-ABA0C2C0227BQ35748849-4FCCAC56-B660-420A-A8B8-114CBF43924B
P2860
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Zoledronic acid versus pamidro ...... uble-blind, comparative trial.
@en
type
label
Zoledronic acid versus pamidro ...... uble-blind, comparative trial.
@en
prefLabel
Zoledronic acid versus pamidro ...... uble-blind, comparative trial.
@en
P2093
P1433
P1476
Zoledronic acid versus pamidro ...... uble-blind, comparative trial.
@en
P2093
Apffelstaedt J
Coleman RE
Kaminski M
P304
P577
2001-09-01T00:00:00Z